BIB
ProShares Ultra Nasdaq Biotechnology
Price Chart
Latest Quote
$120.14
-1.61 (-1.32%)
Current Price
| Previous Close | $121.75 |
| Open | $121.94 |
| Day High | $121.94 |
| Day Low | $120.14 |
| Volume | 871 |
Fund Information
| Quarterly Dividend / Yield | N/A / 0.33% |
| Net Assets | $78.22M |
| Expense Ratio | 0.95% |
| Category | Trading--Leveraged Equity |
| Fund Family | ProShares |
| Net Asset Value | $118.64 |
| Premium/Discount | 1.27% |
| Quarterly Dividend Yield | 0.33% |
| Exchange | NGM |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $115.50 |
| SMA50 | $106.42 |
| SMA200 | $88.33 |
| RSI | 62.16 |
| ATR | 5.0875 |
| Rel Volume | 0.07 |
Performance History
| Week | -2.44% |
| Month | +17.91% |
| Quarter | +44.61% |
| 6 Months | +46.92% |
| YTD | +50.87% |
| Year | +110.14% |
| 3 Years | +132.72% |
| 5 Years | +19.06% |
| 10 Years | +163.06% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-09-03 | $120.14 | 871 |
| 2026-09-02 | $121.79 | 6,700 |
| 2026-09-01 | $118.55 | 6,800 |
| 2026-08-31 | $116.60 | 9,800 |
| 2026-08-28 | $116.39 | 13,000 |
| 2026-08-27 | $123.15 | 12,300 |
| 2026-08-26 | $123.98 | 3,900 |
| 2026-08-25 | $125.19 | 9,800 |
| 2026-08-24 | $120.91 | 16,700 |
| 2026-08-21 | $122.16 | 14,500 |
| 2026-08-20 | $118.91 | 28,100 |
| 2026-08-19 | $126.22 | 37,700 |
| 2026-08-18 | $111.98 | 18,100 |
| 2026-08-17 | $109.88 | 17,000 |
| 2026-08-14 | $106.87 | 6,200 |
| 2026-08-13 | $107.59 | 6,100 |
| 2026-08-12 | $109.44 | 5,800 |
| 2026-08-11 | $108.55 | 12,700 |
| 2026-08-10 | $108.86 | 10,000 |
| 2026-08-07 | $106.44 | 33,800 |
| 2026-08-06 | $102.70 | 4,500 |
| 2026-08-05 | $101.89 | 5,300 |
| 2026-08-04 | $100.17 | 5,700 |
| 2026-08-03 | $96.08 | 3,700 |
About ProShares Ultra Nasdaq Biotechnology
The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.